Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.80 |
| ▸ | PYGL | P06737 | 4/20 | 0.46 |
| ▸ | PYGM | P11217 | 4/20 | 0.46 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 9/20 | 0.40 |
| ▸ | DRD3 | P35462 | 9/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | HTR1D | P28221 | 2/20 | 0.38 |
| ▸ | HTR1B | P28222 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1573069 | 1.00 | CNR2 (0.80) | CNR2PYGLPYGMGHSRDRD2 | |
| SCHEMBL1572570 | 0.90 | CNR2 (0.81) | CNR2PYGLPYGMGHSRDRD2 | |
| SCHEMBL1572945 | 0.90 | CNR2 (0.81) | CNR2PYGLPYGMGHSRDRD2 | |
| SCHEMBL1572567 | 0.90 | CNR2 (0.81) | CNR2PYGLPYGMGHSRDRD2 | |
| SCHEMBL1572553 | 0.89 | CNR2 (0.80) | CNR2PYGLPYGMGHSRDRD2 | |
| SCHEMBL1572554 | 0.89 | CNR2 (0.80) | CNR2PYGLPYGMGHSRDRD2 | |
| SCHEMBL1572488 | 0.89 | CNR2 (1.00) | CNR2PYGLPYGMHRH4SMYD3 | |
| SCHEMBL1572491 | 0.89 | CNR2 (1.00) | CNR2PYGLPYGMHRH4SMYD3 | |
| SCHEMBL1572622 | 0.88 | CNR2 (0.78) | CNR2PYGLPYGMGHSRDRD2 | |
| SCHEMBL1572620 | 0.88 | CNR2 (0.78) | CNR2PYGLPYGMGHSRDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943658-B2 | Indole indane amide compounds useful as CB2 agonists and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943658-B2 | Indole indane amide compounds useful as CB2 agonists and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2176221-B1 | INDOLE INDANE AMIDE COMPOUNDS USEFUL AS CB2 AGONISTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2176221-A1 | INDOLE INDANE AMIDE COMPOUNDS USEFUL AS CB2 AGONISTS AND METHOD | Bristol-Myers Squibb Company (US) | 2010-04-21 | — | — | EP | disclosed |
| US-20090041722-A1 | INDOLE INDANE AMIDE COMPOUNDS USEFUL AS CB2 AGONISTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-12 | — | — | US | disclosed |
| US-20090041722-A1 | INDOLE INDANE AMIDE COMPOUNDS USEFUL AS CB2 AGONISTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-12 | — | — | US | disclosed |
| WO-2009015169-A1 | INDOLE INDANE AMIDE COMPOUNDS USEFUL AS CB2 AGONISTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041722-A1 | INDOLE INDANE AMIDE COMPOUNDS USEFUL AS CB2 AGONISTS AND METHOD | CNR2, CNR1, GPR68 | CNR2 1/4885PYGL 3829/4885PYGM 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.